
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins using their proprietary PROTAC technology. The company's partnerships with large pharmaceutical companies, along with their promising clinical candidates in oncology and neuroscience, position them for strong growth potential. The recent Rigel Pharmaceuticals partnership for their lead drug candidate, VEPPANU, removes a key commercial overhang and provides necessary capital for their pipeline. With several upcoming data catalysts and a favorable entry point for investors, the company has a bright outlook.
Bears say
Arvinas is a clinical-stage biotechnology company with a promising protein degradation platform that aims to treat a variety of diseases. However, the lack of profitability and uncertainty surrounding their product candidates, particularly ARV-806, indicate that there may be regulatory and commercialization challenges ahead, leading to a negative outlook on the stock. Investors should closely monitor the company's financial performance and the progress of their clinical development program.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares